Individuals taking glucagon-like peptide-1 (GLP-1) medications for weight loss may be less inclined to engage in physical activity, according to preliminary research. A study examining data from users of these drugs, which include semaglutide (the active ingredient in Ozempic and Wegovy), found a notable decrease in exercise levels after starting the medication.
Activity Levels Decline
Researchers from HSHS Saint John’s Hospital in Illinois and other institutions analyzed Fitbit data from 753 individuals with obesity who were prescribed GLP-1 medications. The study focused on participants with available activity data both before and after their prescription. The GLP-1 medications included newer options like semaglutide and tirzepatide, as well as older ones such as liraglutide and dulaglutide.
The findings revealed an overall reduction in physical activity among GLP-1 users. The average number of daily steps dropped from 5,047 to 4,487. Additionally, daily moderate-to-vigorous physical activity decreased from an average of 28 minutes to 22 minutes. The study also noted that this decline was more pronounced in men and in individuals who reported experiencing some level of musculoskeletal pain.
Importance of Exercise Management
While GLP-1 therapies have significantly advanced weight loss treatment, the research suggests that exercise habits might be impacted. Historically, exercise has been recommended alongside diet for weight management, helping to preserve lean body mass and muscle strength during weight loss. Although exercise is not typically the primary driver of weight loss for most people, its role in maintaining physical function remains important.
The study’s findings are set to be presented at ENDO 2026, the Endocrine Society’s annual meeting, indicating that the results are preliminary and should be interpreted with caution. While other research, including large-scale clinical trials, has not identified muscle loss as a major concern for GLP-1 users and has suggested improvements in physical functioning, the current study raises questions about adherence to exercise routines.
The researchers emphasized that exercise is beneficial for overall health regardless of weight or medication status. They argue that if a significant number of GLP-1 users are reducing their physical activity, it warrants attention. The study authors concluded that weight loss achieved through medication alone may not inherently lead to increased physical activity. They advocate for the development of targeted interventions to encourage patients to maintain their exercise habits alongside pharmacologic therapy.
Mitchell Landsberg is the senior reporter for News Raise and focuses on Technology. Mitchell regularly writes about social media platforms and how influencers, industry and general people use them to communicate and make money.
